Lung Cancer Drug Tabrecta Approved By The FDA — New Hope For People With a Specific Biomarker

Published May 7, 2020

Lung Cancer Drug Tabrecta Approved By The FDA — New Hope For People With a Specific Biomarker

The FDA's approval of Tabrecta marks a historic step in treatment for patients battling aggressive lung cancer. Researchers say this is just the beginning.

NOW
PLAYING
Cancer Doesn't Mean the End—Senator Harry Reid Talks To SurvivorNet About the Experimental New Therapy That Saved His Life
NOW
PLAYING
Ovarian Cancer Recurrence
NOW
PLAYING
Ovarian Cancer Treatment Decisions
NOW
PLAYING
Immunotherapy Drug Keytruda Approved For Colon Cancer Patients With Specific Tumor Abnormalities
NOW
PLAYING
How Is Calquence Used For Chronic Lymphocytic Leukemia?
NOW
PLAYING
New Hope For Esophageal Cancer Patients -- Immunotherapy Opdivo Approved For Treatment Of Advanced Esophageal Cancer
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.